Wall Street highlights several stocks with warning signs despite optimistic price targets, suggesting cautious investor scrutiny.
AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.
Wall Street highlights several stocks with warning signs despite optimistic price targets, suggesting cautious investor scrutiny.
AstraZeneca proposes a direct NYSE listing to broaden its global investor base and simplify access for U.S. investors, while the company's Enhertu drug shows promising results.